Does Colchicine Prevent Adverse Cardiovascular Events in Gout Patients?

This retrospective study suggests that anti-inflammatory therapies, such as colchicine, are associated with lower CV risk.

Gout and hyperuricemia are associated with excess cardiovascular (CV) risk. However, gout patients often receive colchicine or other anti-inflammatory agents, which might temper the substantial inflammatory component of atherosclerosis. Colchicine is effective for treating patients with pericarditis (NEJM JW Gen Med Oct 1 2013 and N Engl J Med 2013; 369:1522), and it prevented some adverse coronary events in one randomized secondary prevention trial (J Am Coll Cardiol 2013; 61:404). In this retrospective study of 501 gout patients who used colchicine and an equal number of age- and sex-matched non–colchicine users (mean age, 72; median follow-up, 1.3 years), investigators examined the association between colchicine and adverse CV events; mo…

Reviewing Author

Jonathan S. Coblyn, MD

Disclosures

Consultant / Advisory BoardCVS Health

Editorial BoardsUpToDate

Jonathan S. Coblyn, MD

Disclosures

Consultant / Advisory BoardCVS Health

Editorial BoardsUpToDate

Does Colchicine Prevent Adverse Cardiovascular Events in Gout Patients?

Topics

Reviewing Author